Lenexa, Kansas-based cell-based immunotherapy cancer treatment startup TVAX Biomedical has raised $2 million via the first closing of a targeted $10 million private round of financing. The company is currently in clinical trials for what it describes as “a personalized combination of cancer cell vaccination and ‘killer’ T cell treatment.” [Source: FinSMEs]